Q2 revenue grew 20% year-over-year to nearly $1 billion, driven by strong commercial execution and the successful Amicus integration. Raised full-year guidance for revenue and EPS, with VOXZOGO, GALAFOLD, and POMBILITI/OPFOLDA all on track for blockbuster status.Based on BioMarin Pharmaceutical Inc…
Q2 2026 revenue grew 20% year-over-year to $990M, driven by rare disease portfolio strength and Amicus integration. Full-year guidance for revenue, VOXZOGO, and Non-GAAP EPS was raised, with significant cost synergies and accelerated growth expected from the Amicus acquisition.Original document: Bi…
Biotech company BioMarin Pharmaceutical NASDAQ:BMRNwill be reporting results this Thursday after the bell. Here’s what investors should know.BioMarin Pharmaceutical missed analysts’ revenue expectations last quarter, reporting revenues of $766.2 million, up 2.8% year on year. It was a mixed quarter…
